Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?
Roche is increasingly looking like a notable contender in this fast-growing area.
We haven't written up this one. Motley Fool has the full story — the link below goes straight to it.
Also reported by 2 other outlets
- Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market. fool.com
- Lilly Just Reported More Than Half of Patients on Its New Weight Loss Drug Lost 20% of Their Body Weight — and a Third Lost 25%. Here's How the News Could Shake Up the Obesity Drug Market. nasdaq.com
